Article

# ABO Blood Group and the Risk of Pancreatic Cancer

[more]
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
(Impact Factor: 12.58). 04/2009; 101(6):424-31. DOI: 10.1093/jnci/djp020
Source: PubMed

ABSTRACT

Other than several rare, highly penetrant familial syndromes, genetic risk factors for sporadic pancreatic cancer are largely unknown. ABO blood type is an inherited characteristic that in previous small studies has been associated with the risk of gastrointestinal malignancies.
We separately examined the relationship between ABO blood type and the risk of incident pancreatic cancer in two large, independent, prospective cohort studies (the Nurses' Health Study and Health Professionals Follow-up Study) that collected blood group data on 107 503 US health professionals. Hazard ratios for pancreatic cancer by ABO blood type were calculated using Cox proportional hazards models with adjustment for other known risk factors, including age, tobacco use, body mass index, physical activity, and history of diabetes mellitus. All statistical tests were two-sided.
During 927 995 person-years of follow-up, 316 participants developed pancreatic cancer. ABO blood type was associated with the risk of developing pancreatic cancer (P = .004; log-rank test). Compared with participants with blood group O, those with blood groups A, AB, or B were more likely to develop pancreatic cancer (adjusted hazard ratios for incident pancreatic cancer were 1.32 [95% confidence interval {CI} = 1.02 to 1.72], 1.51 [95% CI = 1.02 to 2.23], and 1.72 [95% CI = 1.25 to 2.38], respectively). The association between blood type and pancreatic cancer risk was nearly identical in the two cohorts (P(interaction) = .97). Overall, 17% of the pancreatic cancer cases were attributable to inheriting a non-O blood group (blood group A, B, or AB). The age-adjusted incidence rates for pancreatic cancer per 100 000 person-years were 27 (95% CI = 23 to 33) for participants with blood type O, 36 (95% CI = 26 to 50) for those with blood type A, 41 (95% CI = 31 to 56) for those with blood type AB, and 46 (95% CI = 32 to 68) for those with blood type B.
In two large, independent populations, ABO blood type was statistically significantly associated with the risk of pancreatic cancer. Further studies are necessary to define the mechanisms by which ABO blood type or closely linked genetic variants may influence pancreatic cancer risk.

### Full-text

Available from: Patricia Hartge,
• Source
• "It also indicates that one out of five of the studied population is probably at elevated risk of pancreatic and other types of cancer. For instance, early independent studies showed association of rectal, cervical, leukemia, pancreatic, breast, ovarian, gastric cancers among individuals with blood groups A, AB, or B more likely to have elevated risk of pancreatic cancer than individual belonging to blood group O (Wolpin et al., 2009; Greer et al., 2010; Amundadottir et al., 2009) This study also found that, Rh (+ve) blood group is dominant in Chittagong which is consistent with the available data from previous reports of other population in Bangladesh. Moreover, Rh (+ve) group remains higher than Rh (-ve) group throughout the world (Table 4). "
##### Article: Study of ABO and Rh-D blood group among the common people of Chittagong city corporation area of Bangladesh
[Hide abstract]
ABSTRACT: This study was aimed to identify the distribution patterns of ABO and Rh-D blood group among the population of Chittagong city corporation area in Chittagong city of Bangladesh in order to promote social awareness, and safe blood transfusion among the population. A cross sectional, analytical study was carried out on a total of 937 people in three different area of Chittagong City Corporation (that is, Central railway building area, District commissioner hill area and Patenga sea beach area). The ABO blood group system in the total sample showed the same trend of prevalence with that of the general Indian subcontinent (B > O > A > AB). The same trend was found among males, but among females the order of prevalence was different (O > A > B > AB). Rh-D positive were 90.72% and Rh-D negative were 9.28%. Study of blood grouping is not only generating a simple database but also create a great social awareness about self-blood grouping and safe blood transfusion among the population of a country.
08/2015; 7(9):305-310. DOI:10.5897/JPHE2015.0727
• Source
• "Several studies have indicated a relationship between the risk of pancreatic cancer (PC) and ABO blood group (BG) status [5] [6] [7]. The a1,2-fucosyltransferases FUT1 and FUT2 catalyze the addition of fucose to the galactose residues in Galb1–3GlcNAc-R and Galb1– 4GlcNAc-R glycans to form H type 1 and 2 antigens, respectively. "
##### Article: Hypoxia inducible factor 1α down regulates cell surface expression of α1,2-fucosylated glycans in human pancreatic adenocarcinoma cells
[Hide abstract]
ABSTRACT: The α1,2-fucosyltransferase activity in pancreatic tumors is much lower compared to normal pancreatic tissue. Here we here show that hypoxia inducible factor (HIF) 1α is constitutively expressed in the pancreatic cancer cell lines Pa-Tu-8988S and Pa-Tu-8988T and suppresses the expression of the α1,2-fucosyltransferase genes FUT1 and FUT2. Down regulation of HIF-1α expression resulted in elevated FUT1 and FUT2 transcript levels and an increased expression of α1,2-fucosylated glycan structures on the surface of these cells. In conclusion, our data are the first to identify HIF-1α as a suppressor of FUT1/2 expression, thereby regulating α1,2-fucosylation of cell-surface glycans. Copyright © 2015. Published by Elsevier B.V.
FEBS letters 07/2015; 589(18). DOI:10.1016/j.febslet.2015.07.035 · 3.17 Impact Factor
• Source
• "Some studies included multiple cancer sites, and we analyzed these data separately by site, and the total number of studies by site is 123. Among these studies, we identified 36 studies reported results on gastric cancer (AIRD et al., 1953; AIRD et al., 1954; BILLINGTON, 1956; SEGI et al., 1957; BUCKWALTER et al., 1958; EISENBERG et al., 1958; MACMAHON et al., 1958; BIRNBAUM et al., 1959; BEASLEY et al., 1960; DOLL et al., 1960; BECKMAN et al., 1961; COTTER et al., 1961; NEWMAN et al., 1961; Hartmann et al., 1964; LISKER et al., 1964; Hoskins et al., 1965; Macafee et al., 1967; Glober et al., 1971; van Wayjen et al., 1973; Newell et al., 1974; Akumabor et al., 1986; Kurtenkov et al., 1995; Klaamas et al., 1999; Su et al., 2001; Kamlesh et al., 2005; El et al., 2007; Edgren et al., 2010; Akhtar et al., 2010; Nakao et al., 2011; Qiu et al., 2011; Urun et al., 2012; Wang et al., 2012; Gong et al., 2012; Rizzato et al., 2013; Song et al., 2013), 13 studies on pancreatic cancer (AIRD et al., 1960; Newell et al., 1974; Annese et al., 1990; Wolpin et al., 2009; Greer et al., 2010; Wolpin et al., 2010; Ben et al., 2011; Nakao et al., 2011; Engin et al., 2012; Gong et al., 2012; Wang et al., 2012; Woo et al., 2013; Rizzato et al., 2013), 11 studies on breast cancer (AIRD et al., 1954; BUCKWALTER et al., 1958; MITRA et al., 1962; Hartmann et al., 1964; Newell et al., 1974; Anderson et al., 1984; Costantini et al., 1990; Ronco et al., 2009; Dede et al., 2010; Gates et al., 2012; Urun et al., 2012), 8 studies on cervical cancer ( SEGI et al., 1957; MITRA et al., 1962; ROTKIN et al., 1965; "
##### Article: ABO Blood Groups and Risk of Cancer: a Systematic Review and Meta-analysis
[Hide abstract]
ABSTRACT: Background: For decades, studies have been performed to evaluate the association between ABO blood groups and risk of cancer. However, whether ABO blood groups are associated with overall cancer risk remains unclear. We therefore conducted a meta-analysis of observational studies to assess this association. Materials and methods: A search of Pubmed, Embase, ScienceDirect, Wiley, and Web of Knowledge databases (to May 2013) was supplemented by manual searches of bibliographies of key retrieved articles and relevant reviews. We included case-control studies and cohort studies with more than 100 cancer cases. Results: The search yielded 89 eligible studies that reported 100,554 cases at 30 cancer sites. For overall cancer risk, the pooled OR was 1.12 (95%CI: 1.09-1.16) for A vs. non- A groups, and 0.84 (95%CI: 0.80-0.88) for O vs. non-O groups. For individual cancer sites, blood group A was found to confer increased risk of gastric cancer (OR=1.18; 95%CI: 1.13-1.24), pancreatic cancer (OR=1.23; 95%CI: 1.15-1.32), breast cancer (OR=1.12; 95%CI: 1.01-1.24), ovarian cancer (OR=1.16; 95%CI: 1.04-1.27), and nasopharyngeal cancer (OR=1.17; 95%CI: 1.00-1.33). Blood group O was found to be linked to decreased risk of gastric cancer (OR=0.84; 95%CI: 0.80-0.88), pancreatic cancer (OR=0.75; 95%CI: 0.70-0.80), breast cancer (OR=0.90; 95%CI: 0.85-0.95), colorectal cancer (OR=0.89; 95%CI: 0.81-0.96), ovarian cancer (OR=0.76; 95%CI: 0.53-1.00), esophagus cancer (OR=0.94; 95%CI: 0.89-1.00), and nasopharyngeal cancer (OR=0.81; 95%CI: 0.70-0.91). Conclusions: Blood group A is associated with increased risk of cancer, and blood group O is associated with decreased risk of cancer.
Asian Pacific journal of cancer prevention: APJCP 06/2014; 15(11):4643-50. DOI:10.7314/APJCP.2014.15.11.4643 · 2.51 Impact Factor